rentradВестник рентгенологии и радиологииJournal of radiology and nuclear medicine0042-46762619-0478Limited Liability Company "LUCHEVAYA DIAGNOSTIKA", Russian Association of Radiologists10.20862/0042-4676-2020-101-6-373-384rentrad-603Research ArticleОБЗОРЫREVIEWSСовременный подход к лучевой диагностике рака предстательной железы (систематический обзор международных рекомендаций и клинических исследований за период 2014–2020 гг.)Modern Approach in Radiological Diagnosis of Prostate Cancer (Systematic Review of International Clinical Guidelines and Clinical Studies Over 2014–2020)https://orcid.org/0000-0002-8692-1489ВасильевА. В.VasilyevA. V.

Васильев Александр Викторович, врач-рентгенолог

ул. Ленинградская, 68, пос. Песочный, Санкт-Петербург, 197758

Aleksandr V. Vasilyev, Radiologist

ul. Leningradskaya, 68, poselok Pesochnyy, Saint-Petersburg, 197758

24vav42@gmail.comМищенкоА. В.MishchenkoA. V.

Мищенко Андрей Владимирович, д. м. н., профессор Научно-клинического и образовательного центра «Лучевая диагностика и ядерная медицина» ФГБОУ ВО «Санкт-Петербургский государственный университет»; вед. науч. сотр. ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава России; зам. гл. врача ГБУЗ «Городская клиническая онкологическая больница № 1» Департамента здравоохранения г. Москвы

ул. Ленинградская, 68, пос. Песочный, Санкт-Петербург, 197758Университетская наб., 7/9, Санкт-Петербург, 199034ул. Бауманская, 17/1, Москва, 105005 

Andrey V. Mishchenko, Dr. Med. Sc., Professor of Scientific, Clinical and Educational Center “Radiodiagnostics and Nuclear Medicine”, Saint-Petersburg State University; Leading Researcher, Petrov National Medical Research Center for Oncology, Ministry of Health of the Russian Federation; Deputy Chief Physician, City Clinical Oncology Hospital No. 1, Department of Health of Moscow

ul. Leningradskaya, 68, poselok Pesochnyy, Saint-Petersburg, 197758Universitetskaya naberezhnaya, 7/9, Saint-Petersburg, 199034ul. Baumanskaya, 17/1, Moscow, 105005 

https://orcid.org/0000-0001-5829-6578ПетроваА. С. PetrovaA. S.

Петрова Анна Сергеевна, врач-рентгенолог

ул. Ленинградская, 68, пос. Песочный, Санкт-Петербург, 197758

Anna S. Petrova, Radiologist

ul. Leningradskaya, 68, poselok Pesochnyy, Saint-Petersburg, 197758

https://orcid.org/0000-0003-3850-7109НосовА. К.NosovA. K.

Носов Александр Константинович, к. м. н., ст. науч. сотр., заведующий хирургическим отделением онкоурологии

ул. Ленинградская, 68, пос. Песочный, Санкт-Петербург, 197758

Alexander K. Nosov, Cand. Med. Sc., Senior Researcher, Head of the Surgical Department of Oncourology

ul. Leningradskaya, 68, poselok Pesochnyy, Saint-Petersburg, 197758

https://orcid.org/0000-0002-0940-6491БуськоЕ. А.BuskoE. A.

Бусько Екатерина Александровна, к. м. н., вед. науч. сотр. ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава России; доцент ФГБОУ ВО «Санкт-Петербургский государственный университет»

ул. Ленинградская, 68, пос. Песочный, Санкт-Петербург, 197758Университетская наб., 7/9, Санкт-Петербург, 199034 

Ekaterina A. Busko, Cand. Med. Sc., Leading Researcher, Petrov National Medical Research Center for Oncology, Ministry of Health of the Russian Federation; Associate Professor, Saint-Petersburg State University

ul. Leningradskaya, 68, poselok Pesochnyy, Saint-Petersburg, 197758Universitetskaya naberezhnaya, 7/9, Saint-Petersburg, 199034

https://orcid.org/0000-0002-9902-9414ДаниловВ. В.DanilovV. V.

Данилов Всеволод Вячеславович, врач-рентгенолог

ул. Ленинградская, 68, пос. Песочный, Санкт-Петербург, 197758

Vsevolod V. Danilov, Radiologist

ul. Leningradskaya, 68, poselok Pesochnyy, Saint-Petersburg, 197758

https://orcid.org/0000-0001-6600-6796ШевченкоЕ. Ю. ShevchenkoE. Yu.

Шевченко Елена Юрьевна, клинический ординатор

ул. Ленинградская, 68, пос. Песочный, Санкт-Петербург, 197758

Elena Yu. Shevchenko, Clinical Resident

ul. Leningradskaya, 68, poselok Pesochnyy, Saint-Petersburg, 197758

ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава РоссииРоссияPetrov National Medical Research Center for Oncology, Ministry of Health of the Russian FederationRussian FederationФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава России; ФГБОУ ВО «Санкт-Петербургский государственный университет»; ГБУЗ «Городская клиническая онкологическая больница № 1» Департамента здравоохранения г. МосквыРоссияPetrov National Medical Research Center for Oncology, Ministry of Health of the Russian Federation; Saint-Petersburg State University; City Clinical Oncology Hospital No. 1, Department of Health of MoscowRussian FederationФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава России; ФГБОУ ВО «Санкт-Петербургский государственный университет»РоссияPetrov National Medical Research Center for Oncology, Ministry of Health of the Russian Federation; Saint-Petersburg State UniversityRussian Federation2020250120211016373384Copyright © Васильев А.В., Мищенко А.В., Петрова А.С., Носов А.К., Бусько Е.А., Данилов В.В., Шевченко Е.Ю., 20212021Васильев А.В., Мищенко А.В., Петрова А.С., Носов А.К., Бусько Е.А., Данилов В.В., Шевченко Е.Ю.Vasilyev A.V., Mishchenko A.V.,  Petrova A.S., Nosov A.K., Busko E.A., Danilov V.V.,  Shevchenko E.Y.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.russianradiology.ru/jour/article/view/603

Повышение уровня общего простатспецифического антигена требует дополнительного обследования пациента, для того чтобы не подвергать его излишнему лечению при наличии клинически незначимого рака предстательной железы (кнзРПЖ) и, наоборот, чтобы провести необходимый объем мероприятий при наличии клинически значимого рака предстательной железы (кзРПЖ). В данной статье представлены современные подходы к использованию лучевых методов в системе ведения пациентов с диагнозом или подозрением на рак предстательной железы на основе анализа ключевых публикаций. Для оценки достоинств и недостатков различных методов диагностики РПЖ проведен поиск публикаций за 2014–2020 гг. в базах данных Scopus, Web of Science, PubMed по ключевым словам: prostate cancer, multiparametric MRI, multiparametric ultrasound, PSMA PET/CT. Было отобрано 27 статей. В обзор включены рекомендации Европейской ассоциации урологов, Американского урологического общества, Американской коллегии радиологов и одно практическое руководство.

An increase in the level of prostate-specific antigen requires additional examination of the patient in order not to subject him to unnecessary treatment in case of clinically insignificant prostate cancer and, conversely, to carry out the necessary volume of measures in case of clinically significant prostate cancer. The paper presents the modern solutions for effective usage of diagnostic methods in visualization of clinically significant prostate cancer. To assess the advantages and disadvantages of various methods for diagnosing prostate cancer a search of publications for 2014–2020 period was conducted based on the Scopus, Web of Science, PubMed databases. The request included keywords: prostate cancer, multiparametric MRI, multiparametric ultrasound, PSMA PET/CT. We selected 27 articles. The review includes guidelines from the European Association of Urology, the American Urological Society, the American College of Radiology, and one practice recommendation.

мультипараметрическая магнитно-резонансная томографиярак предстательной железыбиопсия предстательной железыактивное наблюдениеmultiparametric magnetic resonance imagingprostate cancerprostate biopsyactive surveillanceПубликация подготовлена при информационной поддержке компании «Байер»This publication has been prepared with the information support of Bayer.ReferencesIlic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018; 362: k3519. doi: 10.1136/bmj.k3519Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018; 362: k3519. doi: 10.1136/bmj.k3519Chung DY, Kim MS, Lee JS, Goh HJ, Koh DH, Jang WS, et al. Clinical significance of multiparametric magnetic resonance imaging as a preoperative predictor of oncologic outcome in very low-risk prostate cancer. J Clin Med. 2019; 8(4): 542. doi: 10.3390/jcm8040542Chung DY, Kim MS, Lee JS, Goh HJ, Koh DH, Jang WS, et al. Clinical significance of multiparametric magnetic resonance imaging as a preoperative predictor of oncologic outcome in very low-risk prostate cancer. J Clin Med. 2019; 8(4): 542. doi: 10.3390/jcm8040542Mottet N, Cornford P, van den Bergh RCN, Briers E, De Santis M, Fanti S, et al. Prostate cancer: EAU Guideline. Available at: https://uroweb.org/guideline/prostate-cancer/ (accessed October 28, 2020).Mottet N, Cornford P, van den Bergh RCN, Briers E, De Santis M, Fanti S, et al. Prostate cancer: EAU Guideline. Available at: https://uroweb.org/guideline/prostate-cancer/ (accessed October 28, 2020).Sanda MG, Chen RC, Crispino T, Freedland S, Greene K, Klotz LH, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO Guideline; 2017. Available at: https://www.auanet.org/guidelines/prostate-cancer-clinically-localized-guideline (accessed October 28, 2020).Sanda MG, Chen RC, Crispino T, Freedland S, Greene K, Klotz LH, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO Guideline; 2017. Available at: https://www.auanet.org/guidelines/prostate-cancer-clinically-localized-guideline (accessed October 28, 2020).Barr RG, Cosgrove D, Brock M, Cantisani V, Correas JM, Postema AW, et al. WFUMB Guidelines and Recommendations on the clinical use of ultrasound elastography: part 5. Prostate. Ultrasound Med Biol. 2017; 43(1): 27–48. doi: 10.1016/j.ultrasmedbio.2016.06.020Barr RG, Cosgrove D, Brock M, Cantisani V, Correas JM, Postema AW, et al. WFUMB Guidelines and Recommendations on the clinical use of ultrasound elastography: part 5. Prostate. Ultrasound Med Biol. 2017; 43(1): 27–48. doi: 10.1016/j.ultrasmedbio.2016.06.020Mannaerts CK, Wildeboer RR, Postema AW, Hagemann J, Budäus L, Tilki D, et al. Multiparametric ultrasound: evaluation of greyscale, shear wave elastography and contrast-enhanced ultrasound for prostate cancer detection and localization in correlation to radical prostatectomy specimens. BMC Urol. 2018; 18(1): 98. doi: 10.1186/s12894-018-0409-5Mannaerts CK, Wildeboer RR, Postema AW, Hagemann J, Budäus L, Tilki D, et al. Multiparametric ultrasound: evaluation of greyscale, shear wave elastography and contrast-enhanced ultrasound for prostate cancer detection and localization in correlation to radical prostatectomy specimens. BMC Urol. 2018; 18(1): 98. doi: 10.1186/s12894-018-0409-5Kamoi K., Okihara K., Ochiai A., Ukimura O., Mizutani Y., Kawauchi A. The utility of transrectal real-time elastography in the diagnosis of prostate cancer. Ultrasound Med Biol. 2008; 34(7): P1025–32. doi: 10.1016/j.ultrasmedbio.2007.12.002Kamoi K., Okihara K., Ochiai A., Ukimura O., Mizutani Y., Kawauchi A. The utility of transrectal real-time elastography in the diagnosis of prostate cancer. Ultrasound Med Biol. 2008; 34(7): P1025–32. doi: 10.1016/j.ultrasmedbio.2007.12.002Mannaerts CK, Wildeboer RR, Remmers S, Kollenburg RA, Kajtazovic A, Hagemann J, et al. Multiparametric ultrasound for prostate cancer detection and localization: correlation of B-mode, shear wave elastography and contrast enhanced ultrasound with radical prostatectomy specimens. J Urol. 2019; 202(6): 1166–73. doi: 10.1097/JU.0000000000000415Mannaerts CK, Wildeboer RR, Remmers S, Kollenburg RA, Kajtazovic A, Hagemann J, et al. Multiparametric ultrasound for prostate cancer detection and localization: correlation of B-mode, shear wave elastography and contrast enhanced ultrasound with radical prostatectomy specimens. J Urol. 2019; 202(6): 1166–73. doi: 10.1097/JU.0000000000000415Chatfield M, Hicks L, Kaur D, Vivian-Davis C. ACR PI-RADS: prostate imaging and reporting and data system. Version 2.1. Reston, VA, American College of Radiology; 2019. Available at: https://www.acr.org/Clinical-Resources/Reporting-and-DataSystems/PI-RADS (accessed October 28, 2020).Chatfield M, Hicks L, Kaur D, Vivian-Davis C. ACR PI-RADS: prostate imaging and reporting and data system. Version 2.1. Reston, VA, American College of Radiology; 2019. Available at: https://www.acr.org/Clinical-Resources/Reporting-and-DataSystems/PI-RADS (accessed October 28, 2020).Ahmed HU, Bosaily AE, Brown LC, Gabe R, Kaplan R, Parmar M, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017; 389(10071): 815–22. doi: 10.1016/S0140–6736(16)32401–1Ahmed HU, Bosaily AE, Brown LC, Gabe R, Kaplan R, Parmar M, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017; 389(10071): 815–22. doi: 10.1016/S0140–6736(16)32401–1Mehralivand S, Shih JH, Harmon S, Clayton Smith C, Bloom J, Czarniecki M, et al. A grading system for the assessment of risk of extraprostatic extension of prostate cancer at multiparametric MRI. Radiology. 2019; 290(3): 709–19. doi: 10.1148/radiol.2018181278Mehralivand S, Shih JH, Harmon S, Clayton Smith C, Bloom J, Czarniecki M, et al. A grading system for the assessment of risk of extraprostatic extension of prostate cancer at multiparametric MRI. Radiology. 2019; 290(3): 709–19. doi: 10.1148/radiol.2018181278Tosoian JJ, Loeb S, Epstein JI, Turkbey B, Choyke P, Schaeffer EM. Active surveillance of prostate cancer: use, outcomes, imaging, and diagnostic tools. Am Soc Clin Oncol Educ Book. 2016; 35: e235–45. doi: 10.14694/EDBK_159244Tosoian JJ, Loeb S, Epstein JI, Turkbey B, Choyke P, Schaeffer EM. Active surveillance of prostate cancer: use, outcomes, imaging, and diagnostic tools. Am Soc Clin Oncol Educ Book. 2016; 35: e235–45. doi: 10.14694/EDBK_159244Gordon LG, James R, Tuffaha HW, Lowe A, Yaxley J. Cost-effectiveness analysis of multiparametric MRI with increased active surveillance for low-risk prostate cancer in Australia. J Magn Reson Imaging. 2017; 45(5): 1304–15. doi: 10.1002/jmri.25504Gordon LG, James R, Tuffaha HW, Lowe A, Yaxley J. Cost-effectiveness analysis of multiparametric MRI with increased active surveillance for low-risk prostate cancer in Australia. J Magn Reson Imaging. 2017; 45(5): 1304–15. doi: 10.1002/jmri.25504Vos LJ, Janoski M, Wachowicz K, Yahya A, Boychak O, Amanie J, et al. Role of serial multiparametric magnetic resonance imaging in prostate cancer active surveillance. World J Radiol. 2016; 8(4): 410–8. doi: 10.4329/wjr.v8.i4.410Vos LJ, Janoski M, Wachowicz K, Yahya A, Boychak O, Amanie J, et al. Role of serial multiparametric magnetic resonance imaging in prostate cancer active surveillance. World J Radiol. 2016; 8(4): 410–8. doi: 10.4329/wjr.v8.i4.410Calais J, Ceci F, Eiber M, Hope T, Hofman M, Rischpler C, et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019; 20(9): 1286–94. doi: 10.1016/S14702045(19)30415-2Calais J, Ceci F, Eiber M, Hope T, Hofman M, Rischpler C, et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019; 20(9): 1286–94. doi: 10.1016/S14702045(19)30415-2Eissa A, Elsherbiny A, Coelho R, Rassweiler J, Davis JW, Porpiglia F, et al. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature. Minerva Urol Nefrol. 2018; 70(5): 462–78. doi: 10.23736/S0393-2249.18.03081-3Eissa A, Elsherbiny A, Coelho R, Rassweiler J, Davis JW, Porpiglia F, et al. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature. Minerva Urol Nefrol. 2018; 70(5): 462–78. doi: 10.23736/S0393-2249.18.03081-3Hara T, Ogata T, Wada H, Yabukia T, Kanazawa S. Prostate cancer detection with multiparametric MRI: a comparison of 1 M-concentration Gadobutrol with 0.5 M-concentration gadolinium-based contrast agents. Curr. Urol. 2017; 11(4): 201–5. doi: 10.1159/000447219Hara T, Ogata T, Wada H, Yabukia T, Kanazawa S. Prostate cancer detection with multiparametric MRI: a comparison of 1 M-concentration Gadobutrol with 0.5 M-concentration gadolinium-based contrast agents. Curr. Urol. 2017; 11(4): 201–5. doi: 10.1159/000447219Коссов Ф.А., Булычкин П.В., Олимов Б.П., Панов В.О., Ткачев С.И., Буйденок Ю.В. и др. Возможности мультипараметрической магнитно-резонансной томографии в персонализации «спасительной» лучевой терапии у больных с рецидивом рака предстательной железы. Вестник рентгенологии и радиологии. 2018; 99(2): 91–100. doi: 10.20862/0042-46762018-99-2-91-100Kossov FA, Bulychkin PV, Olimov BP, Panov VO, Tkachev SI, Buydenok YuV, et al. Possibilities of multiparametric magnetic resonance imaging in the personalization of salvage radiation therapy in patients with prostate cancer recurrence. Journal of Radiology and Nuclear Medicine. 2018; 99(2): 91–100 (in Russian). doi: 10.20862/0042-4676-2018-99-2-91-100ACR Manual on Contrast Media. 2020. Available at: https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf (accessed December 23, 2020).ACR Manual on Contrast Media. 2020. Available at: https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf (accessed December 23, 2020).ESUR Guidelines on Contrast Agents 10.0. 2018. Available at: http://www.esur.org/fileadmin/content/2019/ESUR_Guidelines_10.0_Final_Version.pdf (accessed December 23, 2020).ESUR Guidelines on Contrast Agents 10.0. 2018. Available at: http://www.esur.org/fileadmin/content/2019/ESUR_Guidelines_10.0_Final_Version.pdf (accessed December 23, 2020).D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280(11): 969–74. doi: 10.1001/jama.280.11.969D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280(11): 969–74. doi: 10.1001/jama.280.11.969Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, MagiGaluzzi C, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol. 2016; 69(3): 428–35. doi: 10.1016/j.eururo.2015.06.046Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, MagiGaluzzi C, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol. 2016; 69(3): 428–35. doi: 10.1016/j.eururo.2015.06.046Klotz LH. Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and undertreatment for aggressive disease. Can J Urol. 2005; 12(Suppl 1): 53–7.Klotz LH. Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and undertreatment for aggressive disease. Can J Urol. 2005; 12(Suppl 1): 53–7.Gaur S, Turkbey B. Prostate MRI for post-treatment evaluation and recurrence. Radiol Clin North Am. 2018; 56(2): 263–75. doi: 10.1016/j.rcl.2017.10.008Gaur S, Turkbey B. Prostate MRI for post-treatment evaluation and recurrence. Radiol Clin North Am. 2018; 56(2): 263–75. doi: 10.1016/j.rcl.2017.10.008Shaish H, Kang SK, Rosenkrantz AB. The utility of quantitative ADC values for differentiating high-risk from low-risk prostate cancer: a systematic review and meta-analysis. Abdom Radiol (NY). 2017; 42(1): 260–70. doi: 10.1007/s00261-016-0848-yShaish H, Kang SK, Rosenkrantz AB. The utility of quantitative ADC values for differentiating high-risk from low-risk prostate cancer: a systematic review and meta-analysis. Abdom Radiol (NY). 2017; 42(1): 260–70. doi: 10.1007/s00261-016-0848-yAlberts AR, Roobol MJ, Drost FJH, Leenders GJ, Bokhorst LP, Bangma CH, et al. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer. BJU Int. 2017; 120(4): 511–9. doi: 10.1111/bju.13836Alberts AR, Roobol MJ, Drost FJH, Leenders GJ, Bokhorst LP, Bangma CH, et al. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer. BJU Int. 2017; 120(4): 511–9. doi: 10.1111/bju.13836Kim JY, Kim SH, Kim YH, Lee HJ, Kim MJ, Choi MS. Low-risk prostate cancer: the accuracy of multiparametric MR imaging for detection. Radiology. 2014; 271(2): 435–44. doi: 10.1148/radiol.13130801Kim JY, Kim SH, Kim YH, Lee HJ, Kim MJ, Choi MS. Low-risk prostate cancer: the accuracy of multiparametric MR imaging for detection. Radiology. 2014; 271(2): 435–44. doi: 10.1148/radiol.13130801Kim TH, Kim CK, Park BK, Jeon HG, Jeong BC, Seo SI, et al. Relationship between Gleason score and apparent diffusion coefficients of diffusion-weighted magnetic resonance imaging in prostate cancer patients. Can Urol Assoc J. 2016; 10(11–12): 377–82. doi: 10.5489/cuaj.3896Kim TH, Kim CK, Park BK, Jeon HG, Jeong BC, Seo SI, et al. Relationship between Gleason score and apparent diffusion coefficients of diffusion-weighted magnetic resonance imaging in prostate cancer patients. Can Urol Assoc J. 2016; 10(11–12): 377–82. doi: 10.5489/cuaj.3896Guo R, Cai L, Fan Y, Jin J, Zhou L, Zhang K. Magnetic resonance imaging on disease reclassification among active surveillance candidates with low-risk prostate cancer: a diagnostic metaanalysis. Prostate Cancer Prostatic Dis. 2015; 18(3): 221–8. doi: 10.1038/pcan.2015.20Guo R, Cai L, Fan Y, Jin J, Zhou L, Zhang K. Magnetic resonance imaging on disease reclassification among active surveillance candidates with low-risk prostate cancer: a diagnostic metaanalysis. Prostate Cancer Prostatic Dis. 2015; 18(3): 221–8. doi: 10.1038/pcan.2015.20Wegelin O, van Melick HH, Hooft L, Bosch JL, Reitsma HB, Barentsz JO, et al. Comparing three different techniques for magnetic resonance imaging-targeted prostate biopsies: a systematic review of in-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus cognitive registration. Is there a preferred technique? Eur Urol. 2017; 71(4): 517–31. doi: 10.1016/j.eururo.2016.07.041Wegelin O, van Melick HH, Hooft L, Bosch JL, Reitsma HB, Barentsz JO, et al. Comparing three different techniques for magnetic resonance imaging-targeted prostate biopsies: a systematic review of in-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus cognitive registration. Is there a preferred technique? Eur Urol. 2017; 71(4): 517–31. doi: 10.1016/j.eururo.2016.07.041Дубицкий Д.Л., Мищенко А.В., Трофименко И.А. Магнитнорезонансная томография предстательной железы. 2-е изд. М.: ГЭOТАР-Медиа; 2021.Dubitskiy DL, Mishchenko AV, Trofimenko IA. Magnetic resonance imaging of the prostate gland. 2nd ed. Мoscow: GEOTARMedia; 2021 (in Russian).

The authors declare that there are no conflicts of interest present.